Abstract

AIM: To study the demographics, treatment and survival analysis in patients diagnosed with carcinoma endometrium METHODS: All patients diagnosed with endometrial cancer treated between January 2014 and July 2019 were included in the study. The details regarding demographics, treatment, post operative histopathology, and outcomes were taken from the case records.All patients were followed upto August 2022. There were 65 patients with median age RESULTS: was 59 years (Range 36 - 77years), with majority of them (61patients) are postmenopausal. 63 patients underwent surgery and 1 patient received radical radiotherapy and 1 patient received palliative chemotherapy. TAH+BSO was done in all patients and lymphnode dissection was done in 54 patients. 48 patients received adjuvant radiotherapy and 25 patients received adjuvant chemotherapy. Predominant postoperative histology is endometrial adenocarcinoma. The pathological stage distribution was stage IA in 15 patients, stage IB in 19 patients, stage II in 5 patients, stage IIIA in 8 patients, stage IIIB in 3 patients and 8 patients in stage IIIC and stage IV in 5 patients. 23 patients had grade I tumors, 11 patients had grade II tumors, and grade III tumors in 7 patientS. Based on the ESMO risk classication, 14 patients had low risk, 16 patients had intermediate and 6 high intermediate, 23 patients were at high risk, and 6 in the advanced risk category. Median follow up is 3years. 3year DFS is 93% and OS is 95%. Diagnosis CONCLUSION: of carcinoma endometrium have increased all over the world in recent years. We have also found the same trend in our institute. One hypothesis for the increased incidence may be due to increase in risk factors like high and rising rates of obesity, few children and diabetes. It is most common in postmenopausal women. Risk factors includes elderly age, menopause, obesity were signicant in present study. Other risk factors were not statistically signicant. Endometrioid adenocarcinoma is the most common histology with early stage among all surgically treated patients. DFS and OS are good in well differentiated, early stage endometrial cancers and but very poor in and poorly differentiated, stage 3 and stage 4 patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call